PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29572451-7	2018	The median peak fold-change during tobramycin exposure for KIM-1 was 2.28 (IQR 2.69) and 4.02 (IQR 7.29) for NGAL, in the absence of serum creatinine changes.	Tobramycin	35-45	lipocalin 2	Homo sapiens	109-113	
27585963-13	2017	Our findings suggest that patient weight and urinary NGAL or RBP could be used to individualize tobramycin therapy in patients with CF.	Tobramycin	96-106	lipocalin 2	Homo sapiens	53-57